CoChat

The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis

Open access
Song, Yu-jia, Li, Shu-ran, Li, Xiao-wan, Chen, Xi, Wei, Ze-xu, Liu, Qing-shan, Cheng, Yong · 2020 · Frontiers in Neuroscience
Cited by 167

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Estrogen replacement therapy (ERT) is a common treatment method for menopausal syndrome, however, its therapeutic value for the treatment of neurological diseases is still unclear. Epidemiological studies were performed and the effect of postmenopausal ERT on treating neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), was summarized by meta-analysis. Methods: 21 articles were selected by systematical searching of contents enlisted on PubMed and Web of Science before June 1, 2019. Epidemiological studies were extracted and relevant research data was obtained from the original articles based on the predefined inclusion criteria and data screening principles. The Comprehensive Meta-Analysis Version 2 software was used to pool effective size, test heterogeneity, conduct meta-regression and subgroup analysis, and calculate publication bias. Results: Our results showed that ERT significantly decreased the risk of onset and/or developing of AD (OR: 0.672; 95% CI: 0.581-0.779; P﹤0.001) and PD (OR: 0.470; 95% CI: 0.368-0.600; P﹤0.001) compared with the control group. Subgroup and meta-regression analysis showed that study design and measure of effect were the source of heterogeneity. Age, sample size, hormone therapy ascertainment, duration of the treatment or route of administration did not play a significant role in affecting the outcome of the meta-analysis. Conclusion: We presented evidence here to support the use of estrogen therapy for the treatment of AD and PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2020.00157

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. Ascherio, 2016, The epidemiology of Parkinson's disease: risk factors and prevention, Lancet. Neurol., 15, 1257, 10.1016/S1474-4422(16)30230-7 · DOI · Paper page
  2. Bagger, 2005, Early postmenopausal hormone therapy may prevent cognitive impairment later in life, Menopause, 12, 12, 10.1097/00042192-200512010-00005 · DOI · Paper page
  3. Becker, 1999, Gender differences in dopaminergic function in striatum and nucleus accumbens, Pharmacol. Biochem. Behav., 64, 803, 10.1016/S0091-3057(99)00168-9 · DOI · Paper page
  4. Brenner, 1994, Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study, Am. J. Epidemiol., 140, 262, 10.1093/oxfordjournals.aje.a117245 · DOI · Paper page
  5. Broe, 1990, A case-control study of Alzheimer's disease in Australia, Neurology, 40, 1698, 10.1212/WNL.40.11.1698 · DOI · Paper page
  6. Currie, 2004, Postmenopausal estrogen use affects risk for Parkinson disease, Arch Neurol., 61, 886, 10.1001/archneur.61.6.886 · DOI · Paper page
  7. Fernandez, 2000, Estrogen use among nursing home residents with a diagnosis of Parkinson's disease, Mov. Disord., 15, 1119, 10.1002/1531-8257(200011)15:6<1119::aid-mds1009>3.0.co;2-0 · DOI
  8. Graves, 1990, A case-control study of Alzheimer's disease, Ann. Neurol., 28, 766, 10.1002/ana.410280607 · DOI · Paper page
  9. Henderson, 2005, Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age, J. Neurol. Neurosurg. Psychiatry, 76, 103, 10.1136/jnnp.2003.024927 · DOI · Paper page
  10. Hogervorst, 2000, The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis, Neuroscience, 101, 485, 10.1016/S0306-4522(00)00410-3 · DOI · Paper page
  11. Imtiaz, 2017, Risk of Alzheimer's disease among users of postmenopausal hormone therapy: a nationwide case-control study, Maturitas, 98, 7, 10.1016/j.maturitas.2017.01.002 · DOI
  12. Kawas, 1997, A prospective study of estrogen replacement therapy and the risk of developing alzheimer's disease: the baltimore longitudinal study of aging, Neurology, 48, 1517, 10.1212/WNL.48.6.1517 · DOI · Paper page
  13. Labandeira-Garcia, 2016, Menopause and Parkinson's disease, Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. Front. Neuroendocrinol., 43, 44, 10.1016/j.yfrne.2016.09.003 · DOI
  14. Lau, 2010, Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia, Alzheimer Dis. Assoc. disord., 24, 56, 10.1097/WAD.0b013e31819d6ec9 · DOI · Paper page
  15. Martignoni, 2003, Reproductive life milestones in women with Parkinson's disease, Funct. Neurol., 18, 211
  16. Martins, 2014, Induction of NAFLD with increased risk of obesity and chronic diseases in developed countries, Open J. Endocr. Metab. Dis., 4, 90, 10.4236/ojemd.2014.44011 · DOI
  17. Martins, 2015, Nutritional and genotoxic stress contributes to diabetes and neurodegenerative diseases such as Parkinson's and Alzheimer's diseases, CNS Neurol. Disord., 3, 158, 10.2174/9781608059263114030008 · doi:10.2174/9781608059263114030008
  18. Martins, 2018, Top 10 Contributions on Genetics, 2
  19. Mortel, 1995, Lack of postmenopausal estrogen replacement therapy and the risk of dementia, J. Neuropsychiatry Clin. Neurosci., 7, 334, 10.1176/jnp.7.3.334 · DOI · Paper page
  20. Mulnard, 2000, Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial, JAMA, 283, 1007, 10.1001/jama.283.8.1007 · DOI · Paper page
  21. Nicoletti, 2007, Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial, Clin. Neuropharmacol., 30, 276, 10.1097/wnf.0b013e318050c9f9 · DOI
  22. Nilsson, 2011, Development of subtype-selective oestrogen receptor-based therapeutics, Nat. Rev. Drug Discov., 10, 778, 10.1038/nrd3551 · DOI · Paper page
  23. O'Brien, 2014, Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease, Epidemiol. Rev., 36, 83, 10.1093/epirev/mxt008 · DOI · Paper page
  24. Paganini-Hill, 1994, Estrogen deficiency and risk of Alzheimer's disease in women, Am. J. Epidemiol., 140, 256, 10.1093/oxfordjournals.aje.a117244 · DOI · Paper page
  25. Park, 2018, Lifetime exposure to estrogen and progressive supranuclear palsy: environmental and genetic PSP study, Mov. Disord., 33, 468, 10.1002/mds.27336 · DOI
  26. Picillo, 2017, The relevance of gender in Parkinson's disease: a review, J. Neurol., 264, 1583, 10.1007/s00415-016-8384-9 · DOI · Paper page
  27. Pike, 2017, Sex and the development of Alzheimer's disease, J. Neurosci. Res., 95, 671, 10.1002/jnr.23827 · DOI · Paper page
  28. Ragonese, 2004, Risk of Parkinson disease in women: effect of reproductive characteristics, Neurology, 62, 2010, 10.1212/WNL.62.11.2010 · DOI · Paper page
  29. Ramirez, 2003, Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice, Neuroendocrinology, 77, 223, 10.1159/000070277 · DOI · Paper page
  30. Roberts, 2006, Postmenopausal estrogen therapy and Alzheimer disease: overall negative findings, Alzheimer Dis. Assoc. Dis., 20, 141, 10.1097/00002093-200607000-00004 · DOI
  31. Rugbjerg, 2013, Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark, Parkinsonism Relat. Dis., 19, 457, 10.1016/j.parkreldis.2013.01.008 · DOI
  32. Seshadri, 2001, Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease, Arch. Neurol., 58, 435, 10.1001/archneur.58.3.435 · DOI
  33. Shao, 2012, Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study, Neurology, 79, 1846, 10.1212/WNL.0b013e318271f823 · DOI · Paper page
  34. Slooter, 1999, Estrogen use and early onset Alzheimer's disease: a population-based study, J. Neurol. Neurosurg. Psychiatry, 67, 779, 10.1136/jnnp.67.6.779 · DOI · Paper page
  35. Slopien, 2018, Menopause and diabetes: EMAS clinical guide, Maturitas, 117, 6, 10.1016/j.maturitas.2018.08.009 · DOI · Paper page
  36. Struble, 2003, Regionally specific modulation of brain apolipoprotein E in the mouse during the estrous cycle and by exogenous 17β estradiol, Exp. Neurol., 183, 638, 10.1016/S0014-4886(03)00215-2 · DOI
  37. Szmuilowicz, 2009, Influence of menopause on diabetes and diabetes risk, Nat. Rev. Endocrinol., 5, 553, 10.1038/nrendo.2009.166 · DOI
  38. Tang, 1996, Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease, Lancet, 348, 429, 10.1016/S0140-6736(96)03356-9 · DOI · Paper page
  39. Venetsanaki, 2019, Menopause and non-alcoholic fatty liver disease: a review focusing on therapeutic perspectives, Curr. Vasc. Pharmacol., 17, 546, 10.2174/1570161116666180711121949 · DOI · Paper page
  40. Waring, 1999, Postmenopausal estrogen replacement therapy and risk of AD: a population-based study, Neurology, 52, 965, 10.1212/WNL.52.5.965 · DOI · Paper page
  41. Xing, 2013, Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer's disease, Prog. Neurobiol., 111, 53, 10.1016/j.pneurobio.2013.09.006 · DOI
  42. Yaffe, 1998, Estrogen therapy in postmenopausal women: effects on cognitive function and dementia, JAMA, 279, 688, 10.1001/jama.279.9.688 · DOI · Paper page
  43. Yesufu, 2007, Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women, Womens Health, 3, 173, 10.2217/17455057.3.2.173 · DOI
  44. Zandi, 2002, Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study, JAMA, 288, 2123, 10.1001/jama.288.17.2123 · DOI · Paper page
  45. Zhao, 2011, Estrogen receptor beta-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause, Menopause, 18, 1131, 10.1097/gme.0b013e3182175b66 · DOI · Paper page

Cited by

See all 167

Metadata

Authors
Song, Y.-J., Li, S.-R., Li, X.-W., Chen, X., Wei, Z.-X., Liu, Q.-S., & Cheng, Y.
Venue
Frontiers in Neuroscience
Published
2020-03-10
Volume
14
Pages
157-157
ISSN
1662-453X (ISSN-L)
OpenAlex
W3011020391
Cited by
167
References
6
FWCI
5.80
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.